Albireo Pharma is a biopharmaceutical company focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company's primary product candidate, A4250, is used for the treatment of progressive familial intrahepatic cholestasis (PFIC), pruritus associated with PFIC, Alagille syndrome and biliary atresia. The company's product candidates in addition to A4250 include elobixibat, which is approved in Japan for the treatment of chronic constipation, and A3384, which is a product candidate to treat bile acid malabsorption.

Amyris is an industrial biotechnology company that applies its technology platform to engineer, manufacture and sell products into the Health and Wellness, Clean Beauty, and Flavor and Fragrance markets. The company's technology platform enables it to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into ingredients. The company is focused on the production of Biofene?, its brand of renewable farnesene, a long-chain, branched hydrocarbon molecule that it manufactures through fermentation using engineered microbes. The company's farnesene derivatives are sold in various products as nutrition, health, skincare, fragrances, solvents, and fragrance ingredients.

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. The company's main product candidate, AT-007, is a central nervous system, penetrant AR inhibitor (ARI) that the company is developing for the treatment of galactosemia, a rare pediatric metabolic disease that affects how the body processes a simple sugar called galactose. The company's second product candidate, AT-001, is an ARI with systemic exposure and peripheral nerve permeability that the company is developing for the treatment of diabetic cardiomyopathy, a fatal fibrosis of the heart.

Ballantyne Strong is a holding company. Through its subsidiaries, the company is focused on serving the cinema, retail, financial, advertising and government markets. The company conducts its operations through three operating segments: Strong Cinema, which provides projection screens, technical support services and other related products to the cinema exhibition industry; Convergent, which delivers digital signage solutions and services to various enterprise markets, including retail, banking and healthcare, as well as certain government agencies and Digital-Out-Of-Home advertising network operators; and Strong Outdoor, which provides advertising services and experiential marketing services.

Cadence is a bank holding company. The company is engaged in commercial lending to middle-market customers and provide a range of commercial loans to middle-market commercial businesses, individuals and business owners. The company's loan portfolio includes commercial and industrial loans, residential real estate loans, commercial real estate loans and other consumer loans. The company also provides its customers a variety of deposit products, including checking accounts, savings accounts, money market accounts and other deposit accounts, through multiple channels, including its network of full-service branches, drive-thru branches, ATMs, ITMs, and its online, mobile and telephone banking platforms.

CenterState Bank is a financial holding company. Through its national bank subsidiary, CenterState Bank, N.A. (the Bank), the company provides a range of consumer and commercial banking services to individuals, businesses and industries through its headquarters branch in Winter Haven, FL. The company also operates, through its Bank, a correspondent banking and capital markets service division for small and medium sized community banks throughout the United States. The company's loans are concentrated in three primary areas: real estate loans, commercial loans and consumer loans. The company's primary deposits include its regular savings, demand, negotiable order of withdrawal, and money market deposit accounts.

Cerecor is a biopharmaceutical company. The company is building a pipeline of therapies in neurology, pediatric healthcare, and orphan rare diseases. The company's neurology pipeline is led by CERC-301, which is in a Phase I safety study for Neurogenic Orthostatic Hypotension. The company is also developing two other neurological clinical and preclinical stage compounds. The company's pediatric orphan rare disease pipeline is led by CERC-801, CERC-802 and CERC-803. All three of these compounds are preclinical therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation by means of substrate replacement therapy.

Cerus is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System for blood safety. The INTERCEPT Blood System, which is based on the company's technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company's INTERCEPT Blood System is for use with three blood components: plasma, platelets, and red blood cells. The platelet system and plasma system are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion and the red blood cell system is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Cryoport provides temperature controlled logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and cold chain logistics knowhow. The company's services are utilized for temperature-controlled shipping and storage and information in the life sciences industry, which includes personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision controlled temperatures.

Durect is a biopharmaceutical company with research and development programs. The company's product pipeline consists of various investigational drug candidates in development. DUR-928, a chemical entity in development, is a candidate in the company's Epigenetic Regulator Program. An endogenous, orally bioavailable small molecule, DUR-928 has been shown in preclinical studies to play an important regulatory role in lipid homeostasis, inflammation, and cell survival. The company's proprietary oral and injectable delivery technologies include POSIMIR? (bupivacaine extended-release solution), an investigational analgesic product intended to deliver bupivacaine to provide up to three days of pain relief after surgery.

Enterprise Products Partners is a provider of midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals and refined products. The company's midstream energy operations include: natural gas gathering, treating, processing, transportation and storage; NGL transportation, fractionation, storage, and export and import terminals; crude oil gathering, transportation, storage, and export and import terminals; petrochemical and refined products transportation, storage, export and import terminals, and related services; and a marine transportation business that operates primarily on the U.S. inland and Intracoastal Waterway systems.

First Financial Bankshares is a financial holding company. Through its subsidiaries, the company conducts commercial banking business. The company's banking centers are located primarily in Central, North Central, Southeast and West Texas. Each of the company's bank regions provides general commercial banking services, which include accepting and holding checking, savings and time deposits, making loans, automated teller machines, drive-in and night deposit services, safe deposit facilities, remote deposit capture, internet banking, mobile banking, payroll cards, transmitting funds, and performing other customary commercial banking services.

Frequency Therapeutics operates as a biotechnology company. The company discovers and develops medicines and small molecule drugs for the treatment of patients with skin disorders, muscle regeneration, and gastrointestinal diseases. The company serves health care sector in the United States.

Honeywell International is a technology and manufacturing company. The company has four segments: Aerospace, which supplies products, software and services for aircrafts; Honeywell Building Technologies, which provides products, software, solutions and technologies including building control and optimization, energy management, access control, video surveillance, fire products, and remote patient monitoring systems; Performance Materials and Technologies, which develops and manufactures chemicals and materials, process technologies and automation solutions; and Safety and Productivity Solutions, which provides products and software that improve productivity, workplace safety and asset performance.

Ingevity is a manufacturer of specialty chemicals and activated carbon materials. The company reports in two business segments: Performance Materials, which manufactures and sells hardwood-based, chemically activated carbon products, produced through a technical and specialized process primarily for use in gasoline vapor emission control systems in cars, trucks, motorcycles and boats; and Performance Chemicals, which is comprised of four application areas (pavement technologies, oilfield technologies, industrial specialties, and engineered polymers), develops, manufactures, and sells a range of specialty chemicals primarily derived from co-products of the kraft pulping process and caprolactone.

International Flavors & Fragrances is a creator and manufacturer of taste, scent and complementary adjacent products, including cosmetic active and natural health ingredients. The company's operating segments are Taste and Scent. The Taste segment develops a range of different flavors and taste offerings for its customers, most of which are tailor-made. The company's Taste business is comprised of various portfolios across flavor compounds, savory solutions, inclusions and nutrition and specialty ingredients. The Scent segment creates fragrance compounds and fragrance ingredients for the household and personal care products. The company also produces cosmetic active and functional ingredients for use in cosmetics.

IsoRay, through its wholly-owned subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other diseases. The company's primary product is its Cs-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body until the physician is satisfied with the radiation dose delivered. The company also provides technical assistance and selling Cs-131 brachytherapy seeds for embedding in collagen tiles by physicians at Barrow Neurological Institute to treat malignant meningioma, primary brain cancers and metastases of cancers to the brain.

Kezar Life Sciences is a clinical-stage biotechnology company, discovering and developing small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The company's product candidate, KZR-616, an immunoproteasome inhibitor, is enrolling a clinical trial across different separate autoimmune indications: lupus nephritis; autoimmune hemolytic anemia, and immune thrombocytopenia; and dermatomyositis, and polymyositis. The company is also utilizing its protein secretion pathway research platform to discover and develop small molecule therapies targeting oncology indications.

La Jolla Pharmaceutical is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for patients suffering from life-threatening diseases. GIAPREZATM (angiotensin II) is approved by the United States Food and Drug Administration as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. LJPC-0118 is the company's investigational product for the treatment of severe malaria. LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product, is being developed for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia and polycythemia vera.

Mirati Therapeutics is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. The company's KRAS inhibitor program is focused on developing inhibitors of KRAS mutations and includes one clinical candidate and a preclinical program. The company also has additional preclinical programs which include product candidates designed to address mutations and tumors where few treatment options exist. The company's clinical and preclinical programs consist of two product candidates: sitravatinib, a multi-kinase inhibitor and MRTX849, a KRAS G12C inhibitor. The company has several discovery programs, including a preclinical program for a KRAS G12D inhibitor.

MTS Systems supplies test, simulation and measurement systems and sensors. The company's Test and Simulation segment provides testing solutions including hardware, software and services. Products, service and customers are grouped into three global sectors: ground vehicles, materials, and structures. The company's Sensors segment is engaged in sensing technologies and solutions used by design engineers and predictive maintenance personnel. Sensors products and solutions serve the automotive, aerospace, industrial, defense, and research and development markets. Sensors products and customers are grouped into four global sectors: positional sensors, test sensors, industrial sensors, and systems sensors.

Northern Oil and Gas is an independent energy company engaged in the acquisition, exploration, development and production of oil and natural gas properties, primarily in the Bakken and Three Forks formations within the Williston Basin in North Dakota and Montana. The company's primary focus is oil exploration and production through non-operated working interests in wells drilled and completed in spacing units that include its acreage. As a non-operator, the company is able to diversify its investment exposure by participating in a number of gross wells, as well as entering into project areas by partnering with operating partners.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.

Parker Drilling is a holding company. Through its subsidiaries, the company is a provider of contract drilling and drilling-related services and rental tools and services. The company has two business lines: Drilling Services, in which the company drills oil, natural gas and geothermal wells with both the company-owned rigs and customer-owned rigs in addition to providing project-related services, such as engineering, project management, operations execution, and quality and safety management; and Rental Tools Services, which provides rental equipment and services to exploration and production companies, drilling contractors, and service companies on land and offshore in the U.S. and select international markets.

PBF Energy is a holding company. Through its subsidiaries, the company is engaged as an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants and other petroleum products in the U.S. The company operates in two business segments: refining, which the company produces a variety of products at each of its refineries such as gasoline, ultra-low-sulfur diesel, heating oil, jet fuel, lubricants, petrochemicals and asphalt; and logistics, which through its PBF Logistics LP subsidiary, the company owns or leases, operates, develops and acquires crude oil and refined petroleum products terminals, pipelines, storage facilities and similar logistics assets.

Penns Woods Bancorp is a bank holding company. Through its subsidiaries, Jersey Shore State Bank (JSSB) and Luzerne Bank (collectively, the Banks), the company is engaged in commercial and retail banking which includes the acceptance of time, savings, and demand deposits, the funding of commercial, consumer, and mortgage loans, and safe deposit services. The Banks provide insurance, securities brokerage services, annuity and mutual fund investment products, and financial planning through JSSB's subsidiary, The M Group, Inc. Services provided by the Banks include accepting time, demand and savings deposits including Super NOW accounts, money market accounts, and fixed rate certificates of deposit.

Reliant Bancorp is a bank holding company. Through its subsidiary, Reliant Bank (the Bank), the company provides a range of banking products and services. The Bank is a full-service community bank. Its principal business is banking, consisting of lending and deposit gathering from (as well as other banking-related products and services) businesses and individuals within the communities it serves, and the operational support to deliver, fund and manage such banking services. Reliant Bank provides a range of commercial banking services for businesses and individuals, including checking, savings, and money market deposit accounts, certificates of deposit and consumer, commercial and real estate loans.

Safehold is a holding company. Through its subsidiaries, the company operates its business through one segment by acquiring, managing and capitalizing ground leases. Ground leases generally represent the ownership of land underlying commercial real estate properties, which are leased on a long-term basis (base terms are 30 to 99 years, often with tenant renewal options) by the land owner to a tenant that owns and operates the building on top of the land, or what the company refer to as a Safehold?.

Simply Good Foods is a developer, marketer and seller of nutritional foods and snacking products. The company's product portfolio consists primarily of nutrition bars, ready-to-drink shakes, snacks and confectionery products marketed under the Atkins?, SimplyProtein?, and Atkins Endulge? brand names. The Atkins brand approach focuses on a healthy eating approach with reduced levels of refined carbohydrates and sugars and encourages the consumption of lean protein, fiber, fruits, vegetables and healthy fats. Through third-party partnerships, the company provides complementary Atkins branded frozen meals.

Unifi manufactures and sells recycled and synthetic products made from polyester and nylon primarily to other yarn manufacturers and knitters and weavers that produce yarn and/or fabric for the apparel, hosiery, home furnishings, automotive, industrial and other end-use markets. The company has four segments: Polyester, which sells polyester-based products to other yarn manufacturers, knitters and weavers that produce yarn and/or fabric; Nylon, which sells nylon-based products to knitters and weavers that produce fabric for the apparel and hosiery markets; and Brazil and Asia, which sells polyester-based products to knitters that produce fabric for the apparel markets in South America and in Asia.

WisdomTree Investments is an asset management company that focuses on exchange-traded products (ETPs). The company operates as an ETP sponsor and asset manager providing investment advisory services globally. Through its subsidiaries, the company provides investment advisory and other management services to its ETPs collectively providing ETPs covering equity, commodity, fixed income, leveraged and inverse, currency and alternative strategies. The company's United States Business segment includes the company's Japan sales office, WTJ, which engaged in selling United States listed exchange-traded funds to Japanese institutions; and the company's International Business segment includes the company's European business and Canadian business.